Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with aztreonam.

H R Stutman1

  • 1Miller Children's Hospital, Long Beach, CA 90801-1428.

The Pediatric Infectious Disease Journal
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Aztreonam is a monobactam antibiotic effective against Gram-negative aerobic infections in adults and children. Clinical studies show high cure rates for various infections, positioning it as a valuable alternative to more toxic therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of quantitative polymerase chain reaction, acid fast bacilli smear, and culture results in patients receiving therapy for pulmonary tuberculosis.

Diagnostic microbiology and infectious disease·1997
Same author

Quantitative-competitive polymerase chain reaction for rapid susceptibility testing of Mycobacterium tuberculosis to isoniazid.

Biochemical and molecular medicine·1997
Same author

Polymerase chain reaction for diagnosis of M. tuberculosis: comparison of simple boiling and a conventional method for DNA extraction.

Biochemical and molecular medicine·1996
Same author

Diagnosis of tuberculosis: can the polymerase chain reaction replace acid-fast bacilli smear and culture?

The Journal of infectious diseases·1995
Same author

Salmonella, Shigella, and Campylobacter: common bacterial causes of infectious diarrhea.

Pediatric annals·1994
Same author

Toxin-related diarrheas.

Pediatric annals·1994
Same journal

Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections.

The Pediatric infectious disease journal·2026
Same journal

Determinants of Severity in Pediatric Viral Lower Respiratory Tract Diseases From Emergency Department Presentation to Hospital Course.

The Pediatric infectious disease journal·2026
Same journal

Oropharyngeal Colonization by Kingella kingae and Septic Arthritis in Children 6-48 Months of Age: A Portuguese Multicenter Case-control Study.

The Pediatric infectious disease journal·2026
Same journal

Trends in Late-onset Sepsis in Very Low Birth Weight Preterm Infants in the Brazilian Network on Neonatal Research: A 10-year Cohort Study.

The Pediatric infectious disease journal·2026
Same journal

Severe Mycoplasma-induced Rash and Mucositis Mimicking Stevens-Johnson Syndrome Treated With Steroid Pulse Therapy: A Case Highlighting Diagnostic Challenges and Therapeutic Considerations.

The Pediatric infectious disease journal·2026
Same journal

Clindamycin Prophylaxis in Pediatric Punctate Outer Retinal Toxoplasmosis.

The Pediatric infectious disease journal·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases

Background:

  • Aztreonam represents a novel class of monobactam antibiotics.
  • It exhibits specific bactericidal activity primarily against Gram-negative aerobic pathogens.
  • It is largely inactive against Gram-positive and anaerobic bacteria.

Purpose of the Study:

  • To evaluate the efficacy and safety of aztreonam for treating serious Gram-negative infections.
  • To assess aztreonam's utility in both adult and pediatric populations.
  • To determine aztreonam's potential role as an alternative to existing therapies.

Main Methods:

  • Clinical studies were conducted in adult and pediatric patients with various bacterial infections.
  • Efficacy was assessed through clinical and microbiologic cure rates.

Related Experiment Videos

  • Safety and tolerability were implicitly evaluated through reported outcomes.

    • Main Results:

    • Aztreonam demonstrated high effectiveness in treating adult infections of the urinary, lower respiratory, musculoskeletal, and female genitourinary tracts.
    • It proved beneficial in neutropenic patients, including those with cancer, and for conditions like peritonitis, gonorrhea, cellulitis, and wound infections.
    • Clinical and microbiologic cure rates ranged from 85% to 100%, comparable to traditional treatments.
    • In children, aztreonam (30 mg/kg every 6–8 hours) achieved satisfactory clinical and microbiologic cure rates for urinary tract and other infections.

    Conclusions:

    • Aztreonam is a highly effective monobactam antibiotic for serious Gram-negative aerobic infections in adults and children.
    • Its favorable efficacy and comparable cure rates suggest it as a viable alternative to more toxic treatments.
    • Further comparative trials are recommended to define aztreonam's precise role in clinical practice.